Omid Vafa

Medicine · Health Sciences

21h-index4.3kcitations35works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(19), Glycosylation and Glycoproteins Research(8), Protein purification and stability(6), CAR-T cell therapy research(6), Chromosomal and Genetic Variations(4)

Publications35 total

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Frontiers in Oncology·2020· 78 citedOpen Access
Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies
Immunology·2019
Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies
Cancer Research·2019
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
mAbs·2019· 98 citedOpen Access
Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies
Frontiers in Immunology·2018· 28 citedOpen Access
Multispecific antibodies targeting CD38 show potent tumor-specific cytotoxicity.
Journal of Clinical Oncology·2018· 2 cited
A novel T-cell bispecific antibody platform for efficient T-cell mediated killing of tumor cells with minimal cytokine release.
Journal of Clinical Oncology·2018· 4 cited
Optimizing production of Fc-amidated peptides by Chinese hamster ovary cells
BMC Biotechnology·2015· 7 citedOpen Access
Secretion of Fc-amidated peptide fusion proteins by Chinese hamster ovary cells
BMC Biotechnology·2015· 6 citedOpen Access
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
Methods·2013· 149 cited
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Journal of Molecular Recognition·2012· 51 cited
Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering
Methods in molecular biology·2011· 41 cited
Comparability assessments of process and product changes made during development of two different monoclonal antibodies
Biologicals·2010· 85 cited
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
mAbs·2010· 239 citedOpen Access
Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge
Proceedings of the National Academy of Sciences·2009· 97 citedOpen Access
Anti-EpCAM XmAb antibodies with improved cytotoxicity
Journal of Clinical Oncology·2006· 1 cited
Engineered antibody Fc variants with enhanced effector function
Proceedings of the National Academy of Sciences·2006· 784 citedOpen Access
A Humanized Anti-CD30 Monoclonal Antibody, XmAb™2513, with Enhanced In Vitro Potency Against CD30-Positive Lymphomas Mediated by High Affinity Fc-Receptor Binding.
Blood·2005· 18 cited
Engineering antibodies to enhance efector functions
Journal of Clinical Oncology·2005
Improving the Efficacy of Rituxan by Rational Protein Engineering.
Blood·2004· 1 cited
page 1 of 2Next →

Frequent Co-authors

Nathan D. Trinklein(7), Jost Vielmetter(6), David F. Carmichael(6), Ute Schellenberger(6), Andrew Boudreau(6), Starlynn Clarke(6), Kevin Dang(6), Suhasini Iyer(6), Brett Jorgensen(6), Payal Pratap(6), Udaya S. Rangaswamy(6), Harshad S. Ugamraj(6), Shelley Force Aldred(6), Duy Pham(5), Ben Buelow(5), Katherine E. Harris(5), Wim van Schooten(5), Greg A. Lazar(4), Wei Dang(4), Sher Karki(4)